Liposarcoma diagnostic study of choice

Jump to navigation Jump to search

Liposarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Liposarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Liposarcoma diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liposarcoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liposarcoma diagnostic study of choice

CDC on Liposarcoma diagnostic study of choice

Liposarcoma diagnostic study of choice in the news

Blogs on Liposarcoma diagnostic study of choice

Directions to Hospitals Treating Liposarcoma

Risk calculators and risk factors for Liposarcoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Sabawoon Mirwais, M.B.B.S, M.D.[2]

Overview

The optimal method for diagnosis of liposarcoma is by biopsy. Biopsy also provides important histopathological information required to identify the sub-type of the liposarcoma.

Diagnostic Study of Choice

Study of Choice

The optimal method for diagnosis of liposarcoma is by biopsy. Biopsy also provides important histopathological information required to identify the sub-type of the liposarcoma.

Subtype Findings
Atypical lipomatous neoplasm (ALN)/Well-differentiated liposarcoma (WDL) 4 subtypes:

Multivacuolated lipoblasts and spindle cells with hyperchromatic nuclei are often observed.
Other findings include fibrotic areas and atypical stromal cells.

De-differentiated liposarcoma Abrupt transition from a low-grade to a high-grade differentiation within the same mass of a well-differentiated liposarcoma.
Myxoid liposarcoma Multinodular mass with round cells and hyaluronic acid matrix.
High cellularity at the periphery and low cellularity at the center of the mass. Mitotic activity is normal and the nuclei are normochromatic.
Pleomorphic liposarcoma Pleomorphic lipoblasts with hyperchromatic nuclei, acidophilic cytoplasm, and eosinophilic hyaline globules.
Spindle cells and multinucleated giant cells may be observed.
Mixed-type liposarcoma Mixed features of myxoid, pleomorphic, and well-differentiated liposarcoma.
Table adapted from Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Geneva:IARC Press; 2002[1] and Enzinger and Weiss's Soft Tissue Tumors , 6th Edition [2]

Staging

The staging of liposarcoma is based on the TNM classification, which includes primary tumor spread, lymph node involvement, and presence of metastasis.

Primary Tumor (T)
Tx Tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor ≤ 5 cm
T1a
Superficial tumor (not invading the fascia)
T1b
Deep tumor
T2 Tumor > 5 cm
T2a
Superficial tumor (not invading the fascia)
T2b
Deep tumor
Retrieved from the National Cancer Institute. Adapted from AJCC: Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 291-8. [3]
Lymph Nodes (N)
NX Lymph nodes cannot be assessed
N0 No regional lymph node involvement
N1 Regional lymph node involvement
Retrieved from the National Cancer Institute. Adapted from AJCC: Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 291-8. [3]
Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Retrieved from the National Cancer Institute. Adapted from AJCC: Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 291-8. [3]
Stages Primary Tumor (T) Lymph Node (N) Metastasis (M) Histopathological Grading
Stage IA T1a, T1b N0 M0 Low grade
Stage IB T2a, T2b N0 M0 Low grade
Stage IIA T1a, T1b N0 M0 High grade
Stage IIB T2a, T2b N0 M0 High grade
Stage III Any T N0, N1 M0 High grade
Stage IV Any T Any N M1 Any grade
Retrieved from the National Cancer Institute. Adapted from AJCC: Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 291-8.[3]

References

  1. Fletcher, Christopher (2002). Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press. ISBN 9283224132.
  2. Goldblum, John (2014). Enzinger and Weiss's soft tissue tumors. Philadelphia, PA: Saunders/Elsevier. ISBN 978-0-323-08834-3.
  3. 3.0 3.1 3.2 3.3 "National Cancer Institute - Stage Information for Adult Soft Tissue Sarcoma".


Template:WikiDoc Sources